The estimated Net Worth of Kenneth Di Pietro is at least $2.29 Milion dollars as of 28 February 2017. Kenneth Pietro owns over 5,696 units of InVivo Therapeutics Corp stock worth over $2,643 and over the last 13 years Kenneth sold NVIV stock worth over $2,283,452.
Sign up
Kenneth Pietro NVIV stock SEC Form 4 insiders trading
Kenneth has made over 14 trades of the InVivo Therapeutics Corp stock since 2013, according to the Form 4 filled with the SEC. Most recently Kenneth exercised 5,696 units of NVIV stock worth $1,823 on 28 February 2017.
The largest trade Kenneth's ever made was exercising 5,696 units of InVivo Therapeutics Corp stock on 28 February 2017 worth over $1,823. On average, Kenneth trades about 1,183 units every 55 days since 2012. As of 28 February 2017 Kenneth still owns at least 8,260 units of InVivo Therapeutics Corp stock.
You can see the complete history of Kenneth Pietro stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kenneth Pietro's mailing address?
Kenneth's mailing address filed with the SEC is C/O INVIVO THERAPEUTICS HOLDINGS CORP., ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE, MA, 02139.
Insiders trading at InVivo Therapeutics Corp
Over the last 14 years, insiders at InVivo Therapeutics Corp have traded over $11,891,061 worth of InVivo Therapeutics Corp stock and bought 364,908 units worth $191,940 . The most active insiders traders include Francis Reynolds, Robert Langer oraz Sean F. Moran. On average, InVivo Therapeutics Corp executives and independent directors trade stock every 24 days with the average trade being worth of $10,438. The most recent stock trade was executed by Brice Foose on 5 February 2023, trading 330,000 units of NVIV stock currently worth $122,100.
What does InVivo Therapeutics Corp do?
about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi
What does InVivo Therapeutics Corp's logo look like?
Complete history of Kenneth Pietro stock trades at Biogen Inc i InVivo Therapeutics Corp
InVivo Therapeutics Corp executives and stock owners
InVivo Therapeutics Corp executives and other stock owners filed with the SEC include:
-
Richard Toselli,
President, Chief Executive Officer, Director, Chief Medical Officer -
Dr. Richard M. Toselli,
Pres, CEO, Chief Medical Officer & Director -
Richard Christopher,
Chief Financial Officer -
Richard C. Christopher,
CFO & Treasurer -
C. Ann Merrifield,
Non-Executive Independent Chairman of the Board -
Robert Rosenthal,
Independent Director -
Richard Roberts,
Independent Director -
Christina Morrison,
Independent Director -
Daniel Marshak,
Independent Director -
Dr. Louis Vaickus FACP, M.D.,
Consultant -
Heather Hamel,
VP of Legal Affairs & Bus. Devel. and Corp. Sec. -
William D'Agostino PE,
Sr. VP of Operations -
Dr. Joseph Philip Vacanti,
Co-Founder -
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
Co-Founder & Member of Scientific Advisory Board -
Tamara L Joseph,
SVP, General Counsel -
Christopher Mc Nulty,
Chief Financial Officer -
Thomas R Ulich,
Chief Scientific Officer -
Masuoka K. Lorianne,
Chief Medical Officer -
Jeffrey S. Hatfield,
Director -
Steven F Mcallister,
Chief Financial Officer -
Kenneth Di Pietro,
Director -
Pamela J Stahl,
Chief Commercial Officer -
Mark D Perrin,
CHIEF EXECUTIVE OFFICER -
John A Jr Mccarthy,
Director -
Bob Rosenthal,
Director -
Brice Foose,
10% owner -
Brian Hess,
Chief Technology Officer -
Sean F. Moran,
Acting Chief Financial Officer -
Gregory D Perry,
Interim CFO -
Francis Reynolds,
CEO, CFO -
Michael J Astrue,
INTERIM CEO -
Adam K Stern,
Director -
Robert Langer,
10% owner -
Edward Wirth,
Chief Science Officer -
George Nolen,
Director -
Heather Hamel,
Chief Legal Officer and GC